辅助奥希替尼：新的治疗标准。
Adjuvant Osimertinib: A New Standard of Care.
机构信息
Division of Hematology, Department of Medicine, Oncology and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24.
Abstract
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) disease, and a superior toxicity profile. This commentary highlights interim results from the ADAURA trial, continuing the effort to establish a role for EGFR TKIs in the adjuvant setting.
摘要
奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（TKI），基于其在总生存期（OS）、中枢神经系统（CNS）疾病控制和更优毒性特征方面的改善，它是转移性非小细胞肺癌（NSCLC）新的一线标准治疗药物。这篇评论重点介绍了 ADAURA 试验的中期结果，该试验继续致力于确定 EGFR TKI 在辅助治疗中的作用。
相似文献
1
Adjuvant Osimertinib: A New Standard of Care.辅助奥希替尼：新的治疗标准。
Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24.
2
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.在辅助治疗中，奥希替尼目前不应被视为EGFR突变型非小细胞肺癌的标准治疗方案。
J Thorac Oncol. 2021 Mar;16(3):371-374. doi: 10.1016/j.jtho.2020.12.003.
3
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.奥希替尼应成为IB至IIIA期表皮生长因子受体（EGFR）突变的非小细胞肺癌辅助治疗的标准治疗方案。
J Thorac Oncol. 2021 Mar;16(3):368-370. doi: 10.1016/j.jtho.2020.11.027.
4
Osimertinib Called "Home Run" for -Mutant NSCLC.奥希替尼被称为 - 突变型 NSCLC 的“本垒打”。
Cancer Discov. 2020 Jul;10(7):896. doi: 10.1158/2159-8290.CD-NB2020-053. Epub 2020 Jun 2.
5
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.未经治的表皮生长因子受体突变型晚期非小细胞肺癌患者奥希替尼对比标准治疗 EGFR-TKI 的治疗进展后结局。
Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.
6
Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.一名接受奥希替尼治疗的肺癌患者发生心室颤动
J Thorac Oncol. 2020 Apr;15(4):e54-e55. doi: 10.1016/j.jtho.2019.11.029.
7
Osimertinib confers potent binding affinity to EGFR kinase domain duplication.奥希替尼对表皮生长因子受体（EGFR）激酶结构域重复序列具有强大的结合亲和力。
Int J Cancer. 2019 Nov 15;145(10):2884-2885. doi: 10.1002/ijc.32617. Epub 2019 Aug 23.
8
Osimertinib for an older de novo T790M patient with chronic kidney disease.奥希替尼用于一名患有慢性肾病的老年初治T790M患者。
Geriatr Gerontol Int. 2018 Mar;18(3):503-504. doi: 10.1111/ggi.13230.
9
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
10
Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.奥希替尼用于治疗EGFR突变型非小细胞肺癌的软脑膜疾病
J Thorac Oncol. 2020 Nov;15(11):1705-1708. doi: 10.1016/j.jtho.2020.08.016. Epub 2020 Oct 23.
引用本文的文献
1
Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.奥希替尼辅助治疗切除的 EGFR 突变型非小细胞肺癌的成本效果建模。
Oncologist. 2022 May 6;27(5):407-413. doi: 10.1093/oncolo/oyac021.
2
Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation.脂质体奥希替尼肺部递药治疗非小细胞肺癌：制剂开发与体外评价。
Drug Deliv Transl Res. 2022 Oct;12(10):2474-2487. doi: 10.1007/s13346-021-01088-0. Epub 2021 Nov 23.
本文引用的文献
1
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.奥希替尼治疗可切除突变型非小细胞肺癌。
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
2
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
3
Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.晚期非小细胞肺癌患者的生物标志物检测：现实世界中的问题与艰难抉择
Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542. doi: 10.1200/EDBK_237863. Epub 2019 May 17.
4
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
5
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
6
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
7
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
8
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.IASLC 肺癌分期项目：对即将发布的（第八版）肺癌 TNM 分类中 TNM 分期分组的修订建议。
J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
9
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.厄洛替尼辅助治疗与安慰剂对照用于 IB 期-IIIA 期非小细胞肺癌患者（RADIANT）：一项随机、双盲、III 期临床试验。
J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
10
Trastuzumab containing regimens for early breast cancer.含曲妥珠单抗的早期乳腺癌治疗方案。
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD006243. doi: 10.1002/14651858.CD006243.pub2.
Zotero 插件